Analysts Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $34.20

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $34.20.

Several equities analysts have weighed in on the company. Wedbush raised their price target on Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, January 4th.

Insider Buying and Selling

In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the sale, the director directly owned 3,833,425 shares in the company, valued at $77,626,856.25. This represents a 6.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors have recently made changes to their positions in the company. HighVista Strategies LLC raised its stake in shares of Tyra Biosciences by 4.3% during the second quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock valued at $239,000 after acquiring an additional 1,021 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after buying an additional 1,668 shares during the period. Federated Hermes Inc. grew its position in shares of Tyra Biosciences by 586.3% during the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after buying an additional 1,841 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Tyra Biosciences by 7.2% during the first quarter. Rhumbline Advisers now owns 28,081 shares of the company’s stock valued at $261,000 after buying an additional 1,879 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Tyra Biosciences by 27.7% during the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after buying an additional 2,766 shares during the period. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA opened at $28.77 on Friday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -15.38 and a beta of 1.07. The firm has a fifty day moving average price of $23.49 and a 200 day moving average price of $16.30. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $30.70.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). As a group, research analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.